Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen in HIV/HBV Co-infection
NCT06497504Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 10
01
Overview
A Phase 2 trial of bepirovirsen in hepatitis B (HBV), sponsored by GSK. Started Sep 2024; status: active, not recruiting.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06497504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497504.